Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
MOTS-c is not FDA-approved and long-term human safety data does not exist
Initially developed for obesity treatment, AOD9604 showed weight-reducing effects in rodent models comparable to those of full-length GH, but without inducing diabetes or stimulating IGF-1 production
AOD9604MetabolicBodyCompositionPrescriptionOnly The metabolic fragment AOD-9604 (Advanced Obesity Drug 9604) is a modified fragment of the GH molecule studied for fat metabolism and lean-mass conversations without stimulating IGF-1 or full GH axis effects the way secretagogues do
Compounded drugs are not FDA-approved, and the FDA does not conduct the same premarket review of compounded products for safety, effectiveness, and quality that it performs for approved drugs
